High-Dose Immunosuppressive Therapy with Autologous Hematopoietic Stem Cell Transplantation as an effective method for treating autoimmune diseases

To date, data have been accumulated indicating the high efficiency of high-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) and the possibility of maintaining and improving the quality of life of patients with autoimmune diseases (AIDs) after it. The experience of using HDIT-AHSCT in the world by 2025 is 30 years, in our country - 27 years. However, despite this, the method is still considered experimental and is not included in the Clinical Guidelines for the relevant nosologies.

Objective - to present an effective potentially single-use method for the treatment of AIDs; to describe the world experience of using HDIT-AHSCT in the treatment of some AIDs.

The article describes the application points and capabilities of the immune reconstitution method for stabilizing and treating severe autoimmune diseases such as systemic scleroderma, systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease, type 1 diabetes mellitus, multiple sclerosis. Thus, HDIT-AHSCT is a highly effective method for treating aggressive and refractory forms of AIDs, provided that it is used in a timely manner - at the stage of predominance of active autoimmune inflammation over the processes of damage to target organs and systems.

1. Alexander T., Farge D., Badoglio M., Lindsay J.O., Muraro P.A., Snowden J.A.; Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic stem cell therapy for autoimmune diseases - Clinical experience and mechanisms. J Autoimmun. 2018;92:35-46. DOI: 10.1016/j.jaut.2018.06.002.

2. Alexander T., Greco R., Snowden J.A. Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Annu Rev Med. 2021;72:215-228. DOI: 10.1146/annurev-med-070119-115617.

3. Cooper G.S., Bynum M.L., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009; 33(3-4):197-207. DOI: 10.1016/j.jaut.2009.09.008.

4. Swart J.F., Delemarre E.M., van Wijk F., Boelens J.J., Kuball J., van Laar J.M., Wulffraat N.M. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol. 2017;13(4):244-256. DOI: 10.1038/nrrheum.2017.7.

5. Smilek D.E., Ehlers M.R., Nepom G.T. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech. 2014;7(5):503-513. DOI: 10.1242/dmm.015099.

6. Polushin A.Y., Lopatina E.I., Zalyalov Y.R., Tsynchenko A.A., Totolyan N.A., Kulagin A.D. High-dose immunosuppressive therapy with autologous hematopoietic stem cells transplantation for multiple sclerosis: current view. Cell Ther Transplant 2022;11(2):6-15. DOI: 10.18620/ctt-1866-8836-2022-11-2-6-15.

7. Duarte R.F., Labopin M., Bader P., Basak G.W., Bonini C., Chabannon C., Corbacioglu S., Dreger P., et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525-1552. DOI: 10.1038/s41409-019-0516-2.

8. Afanasyev B.V., Afanasyeva K.S., Barabanshchikova M.V., Bondarenko S.N., Bykova T.A., Vlasova Y.Y., Gevorgian A.G., Golubovskaya I.K., et al. Indications for hematopoietic stem cell transplantation. 2nd Edition. Based on EBMT Recommendations of 2019. 2019;8(4): 101-145. Cellular Therapy and Transplantation 8(4):101-145 (in Russ.). DOI: 10.18620/ctt-1866-8836-2019-8-4-101-145. EDN: DWLMJK.

9. Laureys G., Willekens B., Vanopdenbosch L., Deryck O., Selleslag D., D'Haeseleer M., De Becker A, Dubois B, et al. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurol Belg. 2018;118(2):161-168. DOI: 10.1007/s13760-018-0905-0.

10. Burman J., Tolf A., Hägglund H., Askmark H. Autologous haematopoietic stem cell transplantation for neurological diseases. J Neurol Neurosurg Psychiatry. 2018;89(2):147-155. DOI: 10.1136/jnnp-2017-316271.

11. Sizikova S.A., Lisukov I.A., Kulagin A.D., Kryuchkova I.V., Gilevich A.V., Chernykh E.R., Leplina O.Yu, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in autoimmune diseases. Therapeutic Archive. 2002;74(7): 22-26. (in Russ.). EDN: NBPLDV.

12. Shevchenko Y.L., Novik A.A., Kuznetsov A.N., Afanasyev B.V., Lisukov I.A., Kozlov V.A., Miasnikov A.A., Rukavicin O.A., et al. Autologous transplantation of hematopoietic stem cells in multiple sclerosis: results of a study of the Russian cooperative cell therapy group. Neurological Journal. 2008;13(2):11-18. (in Russ.). EDN: ILJCYP.

13. Tyndall A., Black C., Finke.J, Winkler J., Mertlesmann R., Peter H.H., Gratwohl A. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet. 1997;349(9047):254. DOI: 10.1016/s0140-6736(05)64864-7.

14. Gratwohl A., Tyndall A. Hämatopoietische Stammzelltransplantationen in der Behandlung von Autoimmunkrankheiten [Hematopoietic stem cell transplantations in treatment of autoimmune diseases]. Z Rheumatol. 1997;56(4):173-177 (in Germ.). DOI: 10.1007/s003930050032.

15. Sykes M., Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435(7042):620-627. DOI: 10.1038/nature03728.

16. Tyndall A., Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol. 2005;141(1):1-9. DOI: 10.1111/j.1365-2249.2005.02806.x.

17. Farge D., Marolleau J.P., Zohar S., Marjanovic Z., Cabane J., Mounier N., Hachulla E., Philippe P., et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol. 2002;119(3):726-39. DOI: 10.1046/j.1365-2141.2002.03895.x.

18. Snowden J.A., Sharrack B., Akil M., Kiely D.G., Lobo A., Kazmi M., Muraro P.A., Lindsay J.O. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist. Clin Med (Lond). 2018;18(4):329-334. DOI: 10.7861/clinmedicine.18-4-329.

19. Polushin A.Yu., Zalyalov Yu.R., Totolyan N.A., Kulagin A.D., Skoromets A.A. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: approaches to risk management. Annals of Clinical and Experimental Neurology. 2022;16(3):53-64. (in Russ.). DOI: 10.54101/ACEN.2022.3.7. EDN: OPKPZH.

20. A.Yu., Zalyalov Yu.R., Totolyan N.A., Kulagin A.D., Skoromets A.A. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: a modern view of the method (review of literature). The Scientific Notes of Pavlov University. 2021;28(4):9-21. (in Russ.). DOI: 10.24884/1607-4181-2021-28-4-9-21. EDN: CXTMUV.

21. Cutolo M., Soldano S., Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019;15(7):753-764. DOI: 10.1080/1744666X.2019.1614915.

22. Slobodin G., Rimar D. Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review. Clin Rev Allergy Immunol. 2017;52(2):194-201. DOI: 10.1007/s12016-016-8563-6.

23. Sullivan K.M., Goldmuntz E.A., Keyes-Elstein L., McSweeney P.A., Pinckney A., Welch B., Mayes M.D., Nash R.A., et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018;378(1):35-47. DOI: 10.1056/nejmoa1703327.

24. Ramaswamy S., Jain S., Ravindran V. Hematopoietic stem cell transplantation for auto immune rheumatic diseases. World J Transplant. 2016;6(1):199-205. DOI: 10.5500/wjt.v6.i1.199.

25. Burt R.K., Shah S.J., Dill K., Grant T., Gheorghiade M., Schroeder J., Craig R., Hirano I., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378(9790):498-506. DOI: 10.1016/S0140-6736(11)60982-3.

26. Van Laar J.M., Farge D., Sont J.K., Naraghi K., Marjanovic Z., Larghero J., Schuerwegh A.J., Marijt E.W., et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490-2498. DOI: 10.1001/jama.2014.6368.

27. Kowal-Bielecka O., Fransen J., Avouac J., Becker M., Kulak A., Allanore Y., Distler O., Clements P., et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8): 1327-1339. DOI: 10.1136/annrheumdis-2016-209909.

28. Burt R.K., Farge D. Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer? Nat Rev Rheumatol. 2018;14(4):189-191. DOI: 10.1038/nrrheum.2018.34.

29. Deng Y., Tsao B.P. Advances in lupus genetics and epigenetics. Curr Opin Rheumatol. 2014;26(5):482-492. DOI: 10.1097/BOR.0000000000000086.

30. Marmont A.M., van Lint M.T., Gualandi F., Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus. 1997;6(6):545-548. DOI: 10.1177/096120339700600613.

31. Alexander T., Hiepe F. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: time ready for a paradigm shift? Clin Exp Rheumatol. 2017;35(3):359-361.

32. Jayne D., Passweg J., Marmont A., Farge D., Zhao X., Arnold R., Hiepe F., Lisukov I., et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13(3):168-176. DOI: 10.1191/0961203304lu525oa.

33. Burt R.K., Traynor A., Statkute L., Barr W.G., Rosa R., Schroeder J., Verda L., Krosnjar N., et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295(5): 527-35. DOI: 10.1001/jama.295.5.527.

34. Rossetti M., Spreafico R., Consolaro A., Leong J.Y., Chua C., Massa M., Saidin S., Magni-Manzoni S., et al. TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis. Ann Rheum Dis. 2017;76(2):435-441. DOI: 10.1136/annrheumdis-2015-208992.

35. Leng X.M., Jiang Y., Zhou D.B., Tian X.P., Li T.S., Wang S.J., Zhao Y.Q., Shen T., et al. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation: a 10-year follow-up study. Clin Exp Rheumatol. 2017;35(3):494-499.

36. Cao C., Wang M., Sun J., Peng X., Liu Q., Huang L., Chai Y., Lai K., et al. Autologous peripheral blood haematopoietic stem cell transplantation for systemic lupus erythematosus: the observation of long-term outcomes in a Chinese centre. Clin Exp Rheumatol. 2017;35(3):500-507.

37. Benham H., Nel H.J., Law S.C., Mehdi A.M., Street S., Ramnoruth N., Pahau H., Lee B.T., et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med. 2015;7(290):290ra87. DOI: 10.1126/scitranslmed.aaa9301.

38. Snowden J.A., Kapoor S., Wilson A.G. Stem cell transplantation in rheumatoid arthritis. Autoimmunity. 2008;41(8):625-631. DOI: 10.1080/08916930802198550.

39. Bingham S., Veale D., Fearon U., Isaacs J.D., Morgan G., Emery P., McGonagle D., Reece R., et al. High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis Rheum. 2002;46(3):837-839. DOI: 10.1002/art.10093.

40. Verburg R.J., Flierman R., Sont J.K., Ponchel F., van Dreunen L., Levarht E.W., Welling M.M., Toes R.E., et al. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann Rheum Dis. 2005;64(10):1397-1405. DOI: 10.1136/ard.2004.033332.

41. Magliano D.J., Boyko E.J.; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS. 10th ed. Brussels: International Diabetes Federation; 2021.

42. Ilonen J., Lempainen J., Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol. 2019;15(11):635-650. DOI: 10.1038/s41574-019-0254-y.

43. Alexander T., Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2022;57(7):1055-1062. DOI: 10.1038/s41409-022-01702-w.

44. Fiorina P., Voltarelli J., Zavazava N. Immunological applications of stem cells in type 1 diabetes. Endocr Rev. 2011;32(6):725-754. DOI: 10.1210/er.2011-0008.

45. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1998;128(7):517-523. DOI: 10.7326/0003-4819-128-7-199804010-00001.

46. Voltarelli J.C., Couri C.E., Stracieri A.B., Oliveira M.C., Moraes D.A., Pieroni F., Coutinho M., Malmegrim K.C., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297(14):1568-1576. DOI: 10.1001/jama.297.14.1568.

47. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., Madeira M.I., Malmegrim K.C., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009;301(15):1573-1579. DOI: 10.1001/jama.2009.470.

48. Li L., Shen S., Ouyang J., Hu Y., Hu L., Cui W., Zhang N., Zhuge Y.Z., et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab. 2012;97(5):1729-1736. DOI: 10.1210/jc.2011-2188.

49. Xiang H., Chen H., Li F., Liu J., Su Y., Hao L., Wang F., Wang Z., et al. Predictive factors for prolonged remission after autologous hematopoietic stem cell transplantation in young patients with type 1 diabetes mellitus. Cytotherapy. 2015;17(11):1638-1645. DOI: 10.1016/j.jcyt.2015.07.006.

50. Cantú-Rodríguez O.G., Lavalle-González F., Herrera-Rojas M.Á., Jaime-Pérez J.C., Hawing-Zárate J.Á., Gutiérrez-Aguirre C.H., Mancias-Guerra C., González-Llano O., et al. Long-Term Insulin Independence in Type 1 Diabetes Mellitus Using a Simplified Autologous Stem Cell Transplant. J Clin Endocrinol Metab. 2016;101(5):2141-2148. DOI: 10.1210/jc.2015-2776.

51. Ye L., Li L., Wan B., Yang M., Hong J., Gu W., Wang W., Ning G. Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus. Stem Cell Res Ther. 2017;8(1):90. DOI: 10.1186/s13287-017-0542-1.

52. Zhang J., Hu M., Wang B., Gao J., Wang L., Li L., Chen S., Cui B., et al.Comprehensive assessment of T-cell repertoire following autologous hematopoietic stem cell transplantation for treatment of type 1 diabetes using high-throughput sequencing. Pediatr Diabetes. 2018;19(7):1229-1237. DOI: 10.1111/pedi.12728.

53. van Megen K.M., van 't Wout E.T., Forman S.J., Roep B.O. A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes. Front Immunol. 2018;9:690. DOI: 10.3389/fimmu.2018.00690.

54. Karnell F.G., Lin D., Motley S., Duhen T., Lim N., Campbell D.J., Turka L.A. Maecker H.T., et al. Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. Clin Exp Immunol. 2017;189(3):268-278. DOI: 10.1111/cei.12985.

55. Massey J.C., Sutton I.J., Ma D.D.F., Moore J.J. Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant. Front Immunol. 2018;9:410. DOI: 10.3389/fimmu.2018.00410.

56. Snarski E., Szmurło D., Hałaburda K., Król M., Urbanowska E., Milczarczyk A., Franek E., Wiktor-Jedrzejczak W. An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes. Acta Diabetol. 2015;52(5):881-888. DOI: 10.1007/s00592-015-0724-1.

57. Lakatos P.L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12(38):6102-6108. DOI: 10.3748/wjg.v12.i38.6102.

58. Windsor J.W., Kaplan G.G. Evolving Epidemiology of IBD. Curr Gastroenterol Rep. 2019;21(8):40. DOI: 10.1007/s11894-019-0705-6.

59. Kuenzig M.E., Fung S.G., Marderfeld L., Mak J.W.Y., Kaplan G.G., Ng S.C., Wilson D.C., Cameron F., et al. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology. 2022;162(4):1147-1159.e4. DOI: 10.1053/j.gastro.2021.12.282.

60. Meade S., Luber R.P., Tamilarasan G., Dinneen E., Irving P.M., Samaan M.A. Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics. EMJ. 2021;6(1):49-58.

61. Falloon K.A., Fiocchi C. Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change? EMJ innov. 2022;6(1):40-49. DOI: 10.33590/emjinnov/21-00134.

62. Gomollón F., Dignass A., Annese V., Tilg H., Van Assche G., Lindsay J.O., Peyrin-Biroulet L., Cullen G.J., et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25. DOI: 10.1093/ecco-jcc/jjw168.

63. Peyrin-Biroulet L., Panaccione R., Louis E., Atreya R., Rubin D.T., Lindsay J.O., Siffledeen J., Lukin D.J., et al. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024;22(10):2096-2106. DOI: 10.1016/j.cgh.2024.02.026.

64. Torres J., Mehandru S., Colombel J.F., Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-1755. DOI: 10.1016/S0140-6736(16)31711-1.

65. Snowden J.A., Panés J., Alexander T., Allez M., Ardizzone S., Dierickx D., Finke J., Hasselblatt P., et al. Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. J Crohns Colitis. 2018;12(4):476-488. DOI: 10.1093/ecco-jcc/jjx184.

66. Reider S., Binder L., Fürst S., Hatzl S., Blesl A. Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered? Cells. 2022;11(21):3463. DOI: 10.3390/cells11213463.

67. Pockley A.G., Lindsay J.O., Foulds G.A., Rutella S., Gribben J.G., Alexander T., Snowden J.A. Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. Front Immunol. 2018;9:646. DOI: 10.3389/fimmu.2018.00646.

68. Le Bourhis L., Corraliza A.M., Auzolle C., Ricart E., Hawkey C.J., Lindsay J.O., Clark M.M., Rogler G., et al. Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn’s disease. Gastroenterology. 2017;152(5): S613-S614. DOI: 10.1016/s0016-5085(17)32180-7.

69. Alexander T., Arnold R., Hiepe F., Radbruch A. Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases. Clin Exp Rheumatol. 2016;34(4 Suppl 98):53-57.

70. Corraliza A.M., Ricart E., López-García A., Carme Masamunt M., Veny M., Esteller M., Mayorgas A., Le Bourhis L., et al. Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohn's Disease Patients. J Crohns Colitis. 2019;13(5):634-647. DOI: 10.1093/ecco-jcc/jjy203.

71. Kavanagh D.P., Kalia N. Hematopoietic stem cell homing to injured tissues. Stem Cell Rev Rep. 2011;7(3):672-682. DOI: 10.1007/s12015-011-9240-z.

72. DiNicola C.A., Zand A., Hommes D.W. Autologous hematopoietic stem cells for refractory Crohn's disease. Expert Opin Biol Ther. 2017;17(5):555-564. DOI: 10.1080/14712598.2017.1305355.

73. Burt R.K., Traynor A., Oyama Y., Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood. 2003;101(5):2064-2066. DOI: 10.1182/blood-2002-07-2122.

74. Kreisel W., Potthoff K., Bertz H., Schmitt-Graeff A., Ruf G., Rasenack J., Finke J.Complete remission of Crohn's disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant. 2003;32(3):337-340. DOI: 10.1038/sj.bmt.1704134.

75. Scimè R., Cavallaro A.M., Tringali S., Santoro A., Rizzo A., Montalbano L., Casà A., Cottone M.Complete clinical remission after high-dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn's disease refractory to immunosuppressive and immunomodulator therapy. Inflamm Bowel Dis. 2004;10(6):892-894. DOI: 10.1097/00054725-200411000-00027.

76. Oyama Y., Craig R.M., Traynor A.E., Quigley K., Statkute L., Halverson A., Brush M., Verda L., et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005;128(3):552-563. DOI: 10.1053/j.gastro.2004.11.051.

77. Cassinotti A., Annaloro C., Ardizzone S., Onida F., Della Volpe A., Clerici M., Usardi P., Greco S., et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut. 2008;57(2):211-217. DOI: 10.1136/gut.2007.128694.

78. Burt R.K., Craig R.M., Milanetti F., Quigley K., Gozdziak P., Bucha J., Testori A., Halverson A., et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010;116(26):6123-6132. DOI: 10.1182/blood-2010-06-292391.

79. Hommes D.W., Duijvestein M., Zelinkova Z., Stokkers P.C., Ley M.H., Stoker J., Voermans C., van Oers M.H., et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. J Crohns Colitis. 2011;5(6):543-549. DOI: 10.1016/j.crohns.2011.05.004.

80. Clerici M., Cassinotti A., Onida F., Trabattoni D., Annaloro C., Della Volpe A., Rainone V., Lissoni F., et al. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis. 2011;43(12):946-952. DOI: 10.1016/j.dld.2011.07.021.

81. Kountouras J., Sakellari I., Tsarouchas G., Tsiaousi E., Michael S., Zavos C., Anastasiadou K., Stergiopoulos C., et al. Autologous haematopoietic stem cell transplantation in a patient with refractory Crohn's disease. J Crohns Colitis. 2011;5(3):275-276. DOI: 10.1016/j.crohns.2011.03.004.

82. Hasselblatt P., Drognitz K., Potthoff K., Bertz H., Kruis W., Schmidt C., Stallmach A., Schmitt-Graeff A., et al. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther. 2012;36(8):725-735. DOI: 10.1111/apt.12032.

83. López-García A., Rovira M., Jauregui-Amezaga A., Marín P., Barastegui R., Salas A., Ribas V., Feu F., et al. Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. J Crohns Colitis. 2017;11(10):1161-1168. DOI: 10.1093/ecco-jcc/jjx054.

84. Hernanz N, Sierra M, Volpato N, Núñez-Gómez L, Mesonero F, Herrera-Puente P, García-Gutiérrez V, Albillos A, et al. Autologous haematopoietic stem cell transplantation in refractory Crohn's disease: Experience in our centre. Gastroenterol Hepatol. 2019;42(1):16-22. DOI: 10.1016/j.gastrohep.2018.08.004.

85. Hawkey C.J., Allez M., Clark M.M., Labopin M., Lindsay J.O., Ricart E., Rogler G., Rovira M., et al. Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. JAMA. 2015;314(23):2524-2534. DOI: 10.1001/jama.2015.16700.

86. Lindsay J.O., Allez M., Clark M., Labopin M., Ricart E., Rogler G., Rovira M., Satsangi J., et al. Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol. 2017;2(6):399-406. DOI: 10.1016/S2468-1253(17)30056-0.

87. Brierley C.K., Castilla-Llorente C., Labopin M., Badoglio M., Rovira M., Ricart E., Dierickx D., Vermeire S., et al. Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. J Crohns Colitis. 2018;12(9):1097-1103. DOI: 10.1093/ecco-jcc/jjy069.

88. Ganich E.G., Shchukina O.B., Polushin A.Yu., Zalyalov Yu.R., Kulikov A.N., Dobronravov V.A., Kulagin A.D. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in crohn disease: literature review. New St. Petersburg medical records. 2024;(2):11-24 (in Russ.). DOI: 10.24884/1609-2201-2024-103-2-11-24. EDN: OXALXM.

89. Darlington P.J., Touil T., Doucet J.S., Gaucher D., Zeidan J., Gauchat D., Corsini R., Kim H.J., et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341-354. DOI: 10.1002/ana.23784.

90. Arruda L.C., Lorenzi J.C., Sousa A.P., Zanette D.L., Palma P.V., Panepucci R.A., Brum D.S., Barreira A.A., et al. Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients. Bone Marrow Transplant. 2015;50(3):380-389. DOI: 10.1038/bmt.2014.277.

91. Mancardi G., Sormani M.P., Muraro P.A., Boffa G., Saccardi R.Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. Mult Scler. 2018;24(3):245-255. DOI: 10.1177/1352458517742532.

92. Nash R.A., Hutton G.J., Racke M.K., Popat U., Devine S.M., Griffith L.M., Muraro P.A., Openshaw H., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72(2):159-169. DOI: 10.1001/jamaneurol.2014.3780.

93. Mancardi G.L., Sormani M.P., Gualandi F., Saiz A., Carreras E., Merelli E., Donelli A., Lugaresi A., et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981-988. DOI: 10.1212/WNL.0000000000001329.

94. Atkins H.L., Bowman M., Allan D., Anstee G., Arnold D.L., Bar-Or A., Bence-Bruckler I., Birch P., et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388(10044):576-585. DOI: 10.1016/S0140-6736(16)30169-6.

95. Muraro P.A., Pasquini M., Atkins H.L., Bowen J.D., Farge D., Fassas A., Freedman M.S., Georges G.E., et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol. 2017;74(4):459-469. DOI: 10.1001/jamaneurol.2016.5867.

96. Zhukovsky C., Sandgren S., Silfverberg T., Einarsdottir S., Tolf A., Landtblom A.M., Novakova L., Axelsson M., et al. Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. J Neurol Neurosurg Psychiatry. 2021;92(2): 189-194. DOI: 10.1136/jnnp-2020-323992.

97. Brittain G., Petrie J., Duffy K.E.M., Glover R., Hullock K., Papaioannou D., Roldan E., Beecher C., et al. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ Open. 2024;14(2):e083582. DOI: 10.1136/bmjopen-2023-083582.

98. Burt R.K., Balabanov R., Burman J., Sharrack B., Snowden J.A., Oliveira M.C., Fagius J., Rose J., et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019;321(2):165-174. DOI: 10.1001/jama.2018.18743.

99. Sharrack B., Saccardi R., Alexander T., Badoglio M., Burman J., Farge D., Greco R., Jessop H., et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55(2):283-306. DOI: 10.1038/s41409-019-0684-0.

100. Polushin A.Y., Tsynchenko A.A., Zalyalov Y.R., Lopatina E.I., Totolyan N.A., Kulagin A.D. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: side effects and the tools of their reduction. Cell Ther Transplant. 2022;11(3-4):25-35. DOI:10.18620/ctt-1866-8836-2022-11-3-4-25-35.

101. Muraro P.A., Mariottini A., Greco R., Burman J., Iacobaeus E., Inglese M., Snowden J.A., Alexander T., et al; Attendees of the ECTRIMS Focused Workshop on HSCT. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT. Nat Rev Neurol. 2025. DOI: 10.1038/s41582-024-01050-x.